Siemens Healthineers: All Eyes on Friday as Philips' Pain Offers a Cautionary Tale
Published on 07/29/2026 at 01:32 | Redaktion boerse-global.de
Siemens Healthineers shares edged higher on Tuesday, climbing 1.31 percent to €36.23, as investors trained their sights on Friday's third-quarter earnings release. The modest uptick came despite — or perhaps because of — a brutal session for Dutch rival Philips, whose own quarterly report sent a chill through the medical technology sector.
Philips raised its 2026 Ebita margin forecast to 13.5-14.0 percent from 12.5-13.0 percent, thanks largely to a US tariff refund that delivered a one-off boost. The company's net profit jumped to €386 million from €240 million a year earlier, and revenue inched up 1 percent to €4.4 billion. Yet the stock cratered in double-digit territory. The culprit: comparable new business slipped 1 percent and China continued to underperform. JPMorgan analyst David Adlington pointed to order intake falling short of estimates. For Siemens Healthineers, the parallel is uncomfortable — the Munich-based group faces the same headwinds of helium shortages and a volatile Chinese market as it prepares to open its books.
The Core Question
Friday's numbers, due at 7:00 a.m. MESZ with an analyst call half an hour later, will be judged primarily on two metrics: China's trajectory and the diagnostics division's margin. Berenberg flagged exactly these risks on July 14, downgrading the stock from "Buy" to "Hold" and slashing the price target from €54.00 to €39.00, citing China weakness, diagnostics headwinds and negative currency effects. RBC Capital Markets struck a more optimistic note on July 17, reaffirming a €45.00 target.
The second quarter already showed strain: earnings per share slipped to €0.45 from €0.48, and revenue fell 3.88 percent to €5.68 billion. A repeat pattern in Q3 would test the recent recovery's staying power. Evidence of stabilization, particularly in China, would suggest the worst may be over.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
Positive Signals Amid the Uncertainty
Operationally, Siemens Healthineers has not been idle. The company signed a technology deal with the Divine Grace Medical Center in the Philippines, supplying digital X-ray equipment, a helium-free 1.5-tesla MRI, a linear accelerator for cancer therapy and a 384-slice CT scanner — the first of its kind in the province, according to the parties involved. Since mid-June, it has also been marketing the Cios Fit ID mobile C-arm for orthopedics, a monitor-integrated unit weighing 290 kilograms with a 73-centimeter inner diameter designed for greater surgical flexibility.
A multi-year "Value Partnership" with Vanderbilt Health worth $87 million will modernize imaging and radiation therapy at the US provider. And a joint technology innovation lab with Freiburg University Hospital and the University of Freiburg, backed by around €8 million, will focus on AI-driven radiation therapy. On the diagnostics front, the company unveiled the Atellica Forte series at the ADLM 2026 conference and released a YouGov survey of 155 US healthcare managers: 82 percent had considered expanding lab services in the past year, more than half prioritized lab equipment investment behind AI applications, 81 percent confirmed that lab turnaround times affect patient care, and 65 percent reported staffing shortages. Siemens Healthineers is also deepening its partnership with NVIDIA to develop self-verifying, AI-powered diagnostic workflows.
Buybacks and Technical Picture
A share buyback program of up to €230 million, running from June 2026 to January 2027, continues alongside these operational moves. Between July 20 and 26, the company repurchased 78,345 shares at a weighted average price of €34.66, bringing the total since June to roughly 2.68 million shares.
Siemens Healthineers at a turning point? This analysis reveals what investors need to know now.
Technically, the stock has stabilized but remains far from its highs. At 52-week peak of €49.86 reached in late July 2025, it still trades 27.34 percent below that level. The 200-day moving average sits 8.80 percent above the current price, indicating the long-term downtrend is unbroken. The recent recovery from May's lows and the flurry of positive operational news could set a friendly tone ahead of Friday, but as the Philips episode demonstrated, sentiment can shift sharply on a single data point.
The Verdict
Friday's report will determine which narrative prevails: that the operational headwinds are easing and the buyback plus new contracts signal underlying confidence, or that the structural challenges in China and diagnostics remain unresolved. The analyst conference call at 7:30 a.m. will provide the first real clues. Until then, the stock sits in a familiar holding pattern — buoyed by tactical optimism, weighed down by strategic uncertainty.
Ad
Siemens Healthineers Stock: New Analysis - 29 July
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
